Business Wire

VIDAC-PHARMA

Share
Vidac Pharma Completes $9 Million Series A Financing

Vidac Pharma, a privately-held clinical stage pharmaceutical company developing novel small molecule therapeutics for the treatment of cancer and oncodermatology disease, announced today that it has closed a $9 million a Series A financing round. The financing was led by a new investor, Israel Biotech Fund. Existing investors, including Mivtach Shamir Holdings, also participated in the financing. Dr. Robert Spiegel and Mr. Ed Saltzman, members of Israel Biotech Fund’s Venture Advisory team, will join Vidac’s board of directors. Robert J. Spiegel, MD is former chief medical officer and senior vice president of the Schering-Plough Research Institute. Ed Saltzman is president and founder of Defined Health, a leading business development strategy consulting firm.

Vidac Pharma plans to use the proceeds to advance the development of its lead product, VDA-1102 ointment, which is in Phase 2 clinical trial in patients with actinic keratosis. Actinic keratosis (AK) is one of the most common dermatologic conditions worldwide. It effects an estimated 58 million people in the United States alone with estimated treatment costs in 2004 of $1.2 billion.

“This financing will allow us to advance the clinical development of our lead candidate VDA-1102 as well as progress our pipeline of novel therapeutics into clinical development,” said Oren M. Becker, Ph.D., president and chief executive officer of Vidac Pharma. “We are thrilled by the strong support from our existing investors, and by the addition of Israel Biotech Fund and its new board members who are highly experienced in guiding drugs through clinical development and regulatory approval to commercial success.”

Vidac pharma is dedicated to discovering and developing first-in-class medicines to help people suffering from a range of oncologic and oncodermatologic diseases. Vidac’s breakthrough technology targets the cancer-specific VDAC/HK2 system without affecting the surrounding healthy tissue. It thus holds the promise of delivering novel drugs that are both efficacious and well tolerated by patients.

“The new financing will allow Vidac Pharma to realize its vision of turning breakthrough science in the field of mitochondria and cancer metabolism into first-in-class therapies that help millions of patients suffering from cancer and related diseases.” Said Prof. Max Herzberg, Vidac’s founder and chairman of the board, who is the inventor of VDA-1102.

“We invested in Vidac because we were impressed by the pre-clinical results of the lead compound and management’s ability to build an important company in the field of oncology and oncodermatology,” said David Sidransky, M.D., co-founder & general partner at Israel Biotech Fund. “This investment is in line with our strategy of investing in leading drug discovery and development companies in Israel.”

About Vidac Pharma

Vidac Pharma is a clinical stage innovative biopharmaceutical company dedicated to discovering and developing first-in-class medicines to help people suffering from a range of oncologic and oncodermatologic diseases. Vidac’s breakthrough technology targets the VDAC/HK2 system that is unique to malignant cells. Modulating this target leads to selective apoptosis of cancer cells without affecting the surrounding healthy tissue, and thus holds the promise of delivering novel drugs that are both efficacious and well tolerated by patients. Vidac’s lead product is, VDA-1102, a selective VDAC/HK2 modulator formulated as a topical ointment. This drug successfully completed Phase 1 clinical, and is now in a Phase 2 clinical study in patients suffering from actinic keratosis. For more information regarding Vidac Pharma, please visit www.vidacpharma.com .

About Israel Biotech Fund

Israel Biotech Fund invests in Israeli and Israeli related biotechnology and pharmaceutical companies. The Fund’s goal is to generate strong returns and long term capital appreciation by funding and building sustainable, high value Israel-based biotech companies. For more information regarding Israel Biotech Fund, please visit www.IsraelBiotechFund.com .

Contact:

Donitza
Nahum Donitza nahum@donitza.co.il
Keren Cohen keren@donitza.co.il
T: +972-3-5167336

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Global New Material International: Driving a Green Future Through Innovation17.7.2025 04:41:00 CEST | Press release

As global economic integration accelerates, materials science—the foundation of modern industry—is undergoing a profound transformation. Global New Material International Holdings Limited (GNMI) stands at the forefront of this evolution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716430383/en/ Colored Building-Integrated Photovoltaic modules developed by CQV, a subsidiary of GNMI. At the recent 2nd Sino-European Corporate ESG Best Practice Conference, GNMI was honored with the “Best Practice in Technological Innovation” award for its outstanding commitment to innovation and green development. The judging panel praised the company’s achievements, noting that “GNMI’s innovations have gained broad international recognition. With a clear strategy focused on green manufacturing and sustainability, the company offers viable solutions to reduce dependence on non-renewable resources while advancing eco-friendly production.” T

Andersen Consulting styrker sin platform med tilføjelsen af Baufest16.7.2025 20:07:00 CEST | Pressemeddelelse

Andersen Consulting udvider sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Baufest, et globalt firma inden for digitalt produktdesign og -udvikling. Med mere end 30 års erfaring og kontorer i hele Amerika og Europa er Baufest anerkendt for at kombinere banebrydende teknologi med en dybdegående forståelse af forretningsstrategi og brugeroplevelse. Firmaet tilbyder et omfattende udvalg af tjenester, der omfatter forretningsdesign, udvikling af digitale produkter, data og anvendt AI og cybersikkerhed. Baufest betjener virksomhedskunder på tværs af nøgleindustrier som bank og finans, detailhandel, energi og sundhedspleje med fokus på at skabe målbare forretningsresultater gennem smidig, skalerbar og etisk teknologipraksis. "Vores samarbejde med Andersen Consulting er et vigtigt skridt fremad for de tjenester, vi tilbyder," siger Ángel Pérez Puletti, administrerende direktør for Baufest. "Andersens fulde pakke af specialiserede tjenester bygger på Baufests

ProAmpac Releases 2025 Sustainability Impact Report: A Decade of Flexibility. A Future of Possibilities16.7.2025 18:54:00 CEST | Press release

ProAmpac, a global leader in flexible packaging and material science, announces the release of its 2025 Sustainability Impact Report. This year’s theme, A Decade of Flexibility. A Future of Possibilities. celebrates the company’s decade-long journey of sustainable innovation and sets the foundation for its forward-looking climate and packaging goals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716418035/en/ ProAmpac's 2025 Sustainability Impact Report “As we celebrate ten years of growth and innovation, we remain focused on what lies ahead: accelerating circular packaging, lowering our carbon footprint, and creating shared value for our employees, customers, communities, and partners. Our journey is far from over, but with every step, our purpose becomes clearer, and our momentum stronger,” said Greg Tucker, founder, vice-chairman, and chief executive officer of ProAmpac. Key highlights from the 2025 Impact Report incl

EBRD Extends Partnership With HTEC Through New Round of Financing16.7.2025 16:25:00 CEST | Press release

Loan to support company expansion€60 million EBRD financing to support HTEC’s expansionHTEC will use the funds for new acquisitionsThe EBRD continues to foster growth of the technology sector The European Bank for Reconstruction and Development (EBRD) is stepping up support for the Serbian technology industry by backing HTEC, a Serbia-founded AI-first engineering services and digital product development company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716157421/en/ EBRD extends partnership with HTEC through new round of financing. The Bank is providing a €60 million loan to support HTEC’s expansion through strategic acquisitions that will further improve the company’s positioning in key markets. The Bank is providing a €60 million loan to support HTEC’s expansion through strategic acquisitions that will further improve the company’s positioning in key markets. HTEC and the EBRD began their partnership in 2020 with

OpenX Announces OpenXSelect, an Advanced Supply-Side Targeting and Curation Platform for Brands and Agencies16.7.2025 16:05:00 CEST | Press release

OpenXSelect cuts deal setup time by 50% and doubles reach across CTV, native, app, and web. OpenX Technologies, Inc., a leading supply-side platform, today announced the general availability of OpenXSelect™, a next-generation curation and supply-side targeting platform for brands and agencies. Built to bring buyers closer to supply, OpenXSelect enables them to take full control of inventory quality, activate targeting at scale using a wide range of data—including audience, behavioral, attention, and sustainability—and optimize performance through a streamlined, intuitive interface. OpenX has been the leader in supply-side curation since 2018, when it launched OpenAudience™, a first-of-its-kind solution for data partners, powered by the industry’s first supply-side identity graph. OpenAudience set a new standard for activating audiences directly on the supply side and redefined what data-driven curation could look like. OpenXSelect™ builds on that legacy. Developed in close collaboratio

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye